» Articles » PMID: 33861492

Rare Diseases Research and Policy in Australia: On the Journey to Equitable Care

Overview
Specialty Pediatrics
Date 2021 Apr 16
PMID 33861492
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Almost exactly 10 years after the publication of 'Call for a national plan for rare diseases' in this journal, the Federal Government launched the National Strategic Action Plan for Rare Diseases (the Action Plan) on the 26th of February 2020, in the lead up to Rare Disease Day on the 29th of February - a rare day for rare diseases. The Action Plan is the culmination of effective advocacy by Rare Voices Australia (RVA) and other stakeholders in the rare disease (RD) sector. RVA is the peak body for Australians living with a RD. The organisation works collaboratively with RD organisations, researchers and clinicians. Since the initial call for a RD plan, a number of health-care initiatives and policy changes have gathered apace including expanded antenatal and newborn screening, the increasing application of next generation sequencing and advances in gene and cell therapeutics. The development of new models of care, diagnostic and treatment pathways, and communities of practice have started to ease the considerable burden and inequitable access to care experienced by RD patients and their families. However, much work remains to be done. The Action Plan outlines the actions to bring about the best possible health and well-being outcomes for Australians living with RD. It is centred around three pillars - awareness and education, care and support, research and data - and will be delivered against the principles of person centredness, equity, and sustainable systems and workforce.

Citing Articles

Experiences of Family Members and Patients with Spinal Muscular Atrophy Under the Multi-Level Medical Security System in Shaanxi Province, China: A Mixed Study.

Zhao Y, Ding S, Lin C, Han Y, Zhao M Healthcare (Basel). 2025; 13(2).

PMID: 39857167 PMC: 11765498. DOI: 10.3390/healthcare13020140.


Integrated Care for People Living With Rare Disease: A Scoping Review on Primary Care Models in Organization for Economic Cooperation and Development Countries.

Vidic N, McGlynn A, Abdi F, Tam C, Crampton R, Lim K J Prim Care Community Health. 2025; 16:21501319241311567.

PMID: 39772949 PMC: 11707790. DOI: 10.1177/21501319241311567.


Scoping Review of Economic Analyses of Rare Kidney Diseases.

Angell B, Wang S, Gadsden T, Moorthy M, Malik C, Barratt J Kidney Int Rep. 2024; 9(12):3553-3569.

PMID: 39698356 PMC: 11652074. DOI: 10.1016/j.ekir.2024.09.004.


Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu.

Zhang X, Zhou T, Zhou J, Zhang D, Yang Y, Pan J BMC Health Serv Res. 2024; 24(1):1123.

PMID: 39334210 PMC: 11430509. DOI: 10.1186/s12913-024-11632-6.


RNA variant assessment using transactivation and transdifferentiation.

Nicolas-Martinez E, Robinson O, Pflueger C, Gardner A, Corbett M, Ritchie T Am J Hum Genet. 2024; 111(8):1673-1699.

PMID: 39084224 PMC: 11339655. DOI: 10.1016/j.ajhg.2024.06.018.